In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Vaccinogen Inc. (OTCMKTS:VGEN) reported that Mpm Bioventures Iii L.p. has picked up 134,452 of common stock as of 2017-02-13.

The acquisition brings the aggregate amount owned by Mpm Bioventures Iii L.p. to a total of 134,452 representing a 0.4% stake in the company.

For those not familiar with the company, Vaccinogen, Inc. is a biotechnology company. The Company is the developer of OncoVAX. OncoVAX is an active specific immunotherapy (ASI) that uses the patient’s own cancer cells to create a vaccine that in turn is used to block the return of cancer following surgery. OncoVAX is a patient specific immunotherapy for stage II colon cancer and its technology may have application in other tumor types, such as melanoma and renal cell carcinoma. The OncoVAX patient-specific vaccine consists of sterile, metabolically active, irradiated and non-tumorigenic autologous cancer cells, with or without fresh frozen Bacillus Calmette-Guerin (BCG) bacteria as an adjuvant. The Company has completed a Phase IIIa study of OncoVAX.

A glance at Vaccinogen Inc. (OTCMKTS:VGEN)’s key stats reveals a current market capitalization of 7.24 million based on 37.32 million shares outstanding and a price at last close of 0.169 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2014-12-26, Halldin picked up 934,580 at a purchase price of $5.50. This brings their total holding to 934,580 as of the date of the filing.

On the sell side, the most recent transaction saw Hanna unload 1,000 shares at a sale price of $3.61. This brings their total holding to 224,587.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Vaccinogen Inc (OTCMKTS:VGEN) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.